1. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma
- Author
-
Yunxin Chen, Allison Ching Yee Tso, Teo Ml, Tan D, Teo C, Lee Lk, Gopalakrishnan Sk, Nagarajan C, Melissa Ooi, Wee Joo Chng, Y T Goh, and de Mel S
- Subjects
Male ,Risk ,Oncology ,Proteasome Endopeptidase Complex ,medicine.medical_specialty ,Transplantation Conditioning ,Evidence-based practice ,Review Article ,Medical Oncology ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Staging system ,Societies, Medical ,Multiple myeloma ,Aged ,Singapore ,business.industry ,Incidence (epidemiology) ,Antibodies, Monoclonal ,General Medicine ,Guideline ,Middle Aged ,Plasma cell neoplasm ,medicine.disease ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,Risk stratification ,Quality of Life ,Female ,Multiple Myeloma ,business ,Stem Cell Transplantation ,030215 immunology - Abstract
Multiple myeloma (MM) is an incurable plasma cell neoplasm with an incidence of 100 patients per year in Singapore. Major advances have been made in the diagnosis, risk stratification and treatment of MM in the recent past. The reclassification of a subset of patients with smouldering MM, based on high-risk biomarkers, and the development of the revised international staging system are among the key new developments in diagnosis and staging. The use of novel agent-based treatment has resulted in significant improvements in the survival and quality of life of many patients with MM. Determining the optimal use of proteasome inhibitors, immunomodulators and, more recently, monoclonal antibodies is an area of ongoing investigation. In this guideline, we aim to provide an overview of the management of MM, incorporating the latest developments in diagnosis and treatment.
- Published
- 2017